Actionable news
0
All posts from Actionable news
Actionable news in DVAX: Dynavax Technologies Corporation,

​Dynavax receives thumbs up from FDA Panel - shares surge 82%; FDA request further trial from Tenax TENX - shares down 27%

Price and Volume Movers

Dynavax Technologies Corporation (NASDAQ: DVAX) shares are currently trading up 82% to $16.85 following news that the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted 12 to 1 that the safety data for HEPLISAV-B support approval for the immunization against Hepatitis B infection in adults 18 years of age and older. Three members of the panel abstained. The PDUFA date for the final approval decision is set for August 10, 2017.

Tenax Therapeutics, Inc. (NASDAQ: TENX) announced that the FDA has requested the company conduct an additional trial for its pipeline candidate levosimendan. Its previous Phase 3 trial in January 2017, did not meet the primary endpoint. Shares have slumped in the after-hours session, currently trading down 27% to $0.50. Tenax noted in Friday’s release that “given the size and scope of such a trial, the Company is reviewing clinical, regulatory and financial options with regard to the levosimendan program in the U.S. and Canada.”

Kamada Ltd. (NASDAQ:KMDA) shares slid to...


More